Merck completes $10 billion acquisition of Verona Pharma Oct 7, 2025 06:45AM
Merck Completes Acquisition of Verona Pharma Oct 7, 2025 06:45AM
Merck to acquire Verona Pharma for $10 billion to add COPD treatment Jul 9, 2025 06:30AM
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade Jul 9, 2025 06:30AM
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Feb 27, 2024 07:00AM


Nov 8, 2023 04:01PM Ligand Reports Third Quarter 2023 Financial Results
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Feb 22, 2023 04:01PM Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
Nov 7, 2022 04:01PM Ligand Reports Third Quarter 2022 Financial Results
Aug 8, 2022 04:01PM Ligand Reports Second Quarter 2022 Financial Results
Feb 17, 2022 04:01PM Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 3, 2021 07:30AM Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
Jul 17, 2020 09:29AM Pre-Open Movers 07/17: (APDN) (OCN) (HMHC) Higher; (NIO) (NFLX) (ROKU) Lower (more...)
Mar 12, 2019 10:00AM Ligand Provides Highlights from Today’s Analyst Day Event
Oct 6, 2017 10:00AM Verona Pharma plc (Nasdaq: VRNA) to Ring The Nasdaq Stock Market Closing Bell